Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
31.82
+0.77 (2.48%)
Dec 20, 2024, 4:00 PM EST - Market closed
Avidity Biosciences Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Avidity Biosciences stock have an average target of 64.36, with a low estimate of 45 and a high estimate of 96. The average target predicts an increase of 102.26% from the current stock price of 31.82.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RNA stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 5 | 5 | 6 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 9 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +126.27% | Dec 20, 2024 |
| RBC Capital | RBC Capital | Buy Initiates $67 | Buy | Initiates | $67 | +110.56% | Nov 26, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +104.27% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +88.56% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +88.56% | Oct 31, 2024 |
Financial Forecast
Revenue This Year
8.57M
from 9.56M
Decreased by -10.33%
Revenue Next Year
6.91M
from 8.57M
Decreased by -19.44%
EPS This Year
-2.89
from -2.91
EPS Next Year
-3.27
from -2.89
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 13.4M | 20.7M | 76.1M | |||
| Avg | 8.6M | 6.9M | 23.9M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 40.6% | 141.3% | 1,002.3% | |||
| Avg | -10.3% | -19.4% | 246.0% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.71 | -2.60 | -3.28 | |||
| Avg | -2.89 | -3.27 | -3.83 | |||
| Low | -3.00 | -4.45 | -4.57 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.